Skip to main content
. Author manuscript; available in PMC: 2017 Oct 1.
Published in final edited form as: Expert Opin Biol Ther. 2016 Aug 8;16(10):1303–1309. doi: 10.1080/14712598.2016.1217988

Table 5.

Sarilumab treatment-emergent adverse events in phase III

Event type Description Prevalence (%)
Low/High/Placebo		 Comments
Infections:

  Serious

  Opportunistic		 Infection most
common emergent
adverse event

2.6 / 4.0 / 2.3

0.7 / 0.9 / 0.5		 No cases of TB

One fungal bronchitis

H. Zoster
Abnormal liver
function tests		 ALT more than 3×
ULN		 9.5/ 8.0 / 2.1 24 patients were
discontinued due to
elevations
Elevated total
cholesterol		 From < 240 mg/dl to
≥ 240 mg/dl		 36.8 / 43.0 / 18.3 No cardiac events
Decreased
neutrophil
counts		 0.5 – <1.0 × 109/L

< 0.5 × 109/L		 5.1 / 7.8 / 0.0

0.9 / 0.7 / 0.0		 No relationship of low
neutrophil count to
infections.